Fidelity SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

Provectus Biopharmaceuticals Inc. (PVCT)

PVCT RSS Feed
Add PVCT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Gulfbreeze, Ovidius, buccaneer1961, TOB
Search This Board:
Last Post: 9/22/2014 4:45:49 PM - Followers: 167 - Board type: Free - Posts Today: 0

This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices.




PVCT on YouTube...
http://www.youtube.com/watch?v=nuYpvcnAq4c

http://www.theze.cn/diabetes/cure-for-cancer-provectus-pharmaceutical-pv-10-for-melanoma-story-airs-on-abcs-730-report-in-australia-provectus-pharmaceutical-pvct.html


--------------------------------------------------------------
Letter from the CEO Craig Dee's

We are a group of dedicated and entrepreneurial scientists, working together for the past 10 years, engaged in developing breakthrough technologies for cancer and other serious diseases. Our primary goal at Provectus is to develop alternative treatments that are safer, more effective, less invasive and more economical than conventional therapies.

Our Provectus Pharmatech division develops ethical pharmaceuticals for oncology and dermatology. Looking first to oncology, our novel drugs are designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. In particular, our focus is on melanoma, breast and liver cancers – among the most difficult cancers to treat using conventional methods. We are very excited about the Phase I clinical trials of Provecta™ that began in 2005 for melanoma and breast cancer, and we are expanding to include liver cancer patients soon.

Targeting abnormal or diseased cells is also the approach we use in designing proprietary treatments for dermatological diseases, in particular, chronic, severe cases of psoriasis, eczema and acne. We anticipate that Phase II clinical trials of our topical agent Xantryl™ for psoriasis and eczema will begin soon. In addition, certain skin cancers may be targeted and treated more safely and effectively using Xantryl™.

In addition to our core pharmaceutical work, Provectus has developed a number of intellectual properties and technologies in the areas of medical devices and biotechnologies. Rather than dilute the efforts of Pharmatech, we are actively pursuing licensure, co-development, spin-offs and joint ventures of these technologies via our divisions Provectus Devicetech and Provectus Biotech. Devicetech encompasses both cosmetic and therapeutic treatments, with key attention to developing laser-based products to treat melanoma. Biotech is concentrating on producing vaccines to prevent certain cancers and other serious diseases, as well as detecting new viruses that could be associated with the onset of such diseases.

Our fourth division, Pure-ific Corp., is prepped to be sold or spun off to further develop its over-the-counter products. We are introducing professional skincare products for disposable glove users, and novel retail products for personal hygiene. In addition, we will be introducing an OTC product for acne sufferers.

We are proud of our intellectual capital at Provectus. We hold 15 U.S. patents in the pharmaceutical, medical device and biotech fields, with 19 additional patent applications in the works.

Provectus is a significant, emerging player in the huge and growing pharmaceutical industry. We believe in our potential to improve health care worldwide, using breakthrough products that are easy to manufacture and license, and economical to use. We appreciate your interest in our company, and welcome your comments and questions.


Craig Dees, Ph.D., CEO
Provectus Pharmaceuticals
--------------------------------------------------------------


PVCT 6 months chart:
http://stockcharts.com/h-sc/ui?s=PVCT&p=D&yr=0&mn=6&dy=0&id=p03754661229

Technical analysis:
http://www.stockta.com/cgi-bin/analysis.pl?symb=PVCT&num1=7&cobrand=&mode=stock



PVCT News:
http://finance.yahoo.com/q/h?s=pvct.ob



DETAILED RESEARCH REPORTS:
--------------------------------------------------------------

http://www.pvct.com/analyst_reports.html

--------------------------------------------------------------

PVCT insiders transactions:
http://www.secform4.com/insider/showhistory.php?symbol=pvct

--------------------------------------------------------------


Drug Delivery Technology magazine special feature article "Revisiting Intralesional Delivery of Cancer Treatment", by Provectus CEO Craig Dees, Ph.D., compares Provectus’ novel cancer drugs to current cancer treatments.
http://www.pvct.com/DDTv6n2-SpecialFeature.pdf

--------------------------------------------------------------
May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.

Video can be viewed here.

http://www.pvct.com/hersey_pv10_video.html?pg=2

This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.

Video can be viewed here.

http://www.pvct.com/hersey_pv10_video.html?pg=5
--------------------------------------------------------------
Contact Info

Telephone: +1 (865) 769-4011
Fax: +1 (865) 769-4013
info@pvct.com

Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA

Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Atlas Stock Transfer
5899 South State Street, Suite # 24
Murray, UT 84107
Telephone: +1 (801) 266-7151
Fax: +1 (801) 262-0907

Investor Relations:
Joseph Kessler
The Investor Relations Group
11 Stone St., 3rd fl
New York, NY 10004
Telephone: 212-825-3210
Fax: 212-825-3229
jkessler@investorrelationsgroup.com

Public Relations:
The Investor Relations Group
Janet Vasquez
Telephone: 212-825-3210
janet@theinvestorrelationsgroup.com

Investment Advisor:
Damon Testaverde
Network 1 Financial Securities
Telephone: +1 (800) 205-8031
--------------------------------------------------------------
Share Statistics
Outstanding:
45.45 m
Float:
35.35 m

Non-Corp. Insider Hold'gs:
22.20% (as of 4/1/07)
--------------------------------------------------------------

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PVCT
Current Price
Volume:
Bid Ask Day's Range
Wiki
PVCT News: Current Report Filing (8-k) 05/27/2014 03:45:39 PM
PVCT News: Current Report Filing (8-k) 05/23/2014 02:19:35 PM
PVCT News: Current Report Filing (8-k) 05/21/2014 03:32:59 PM
PVCT News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/20/2014 05:20:44 PM
PVCT News: Statement of Changes in Beneficial Ownership (4) 05/20/2014 06:08:15 AM
News News Alert: Current Report Filing (8-k) 09/22/2014 06:08:53 AM
PostSubject
#3564  Sticky Note Provectus SEC Filings... Gulfbreeze 05/01/14 12:10:06 AM
#3563  Sticky Note PLEASE STICKY THIS INFORMATION laxerpro22 04/30/14 11:21:55 PM
#6565   What does Christopher Kaplan bring to the SAB? vorlon1966 09/22/14 04:45:49 PM
#6564   Re: Merck buys Sigma-Aldrich for $17 billion cash vorlon1966 09/22/14 03:36:47 PM
#6563   Merck buys Sigma-Aldrich for $17 billion cash vorlon1966 09/22/14 02:44:29 PM
#6562   New addition to PVCT's Strategic Advisory Board Gulfbreeze 09/22/14 08:27:33 AM
#6561   new CTD blog post today robofat 09/21/14 05:14:57 PM
#6560   Because Dominic's program picked up the drafts vorlon1966 09/21/14 03:43:52 AM
#6559   Read my latest on yahoo vorlon1966 09/21/14 03:41:29 AM
#6558   Preliminary Program can be downloaded here: http://eventscribe.com/2014/sitc/ I FortStCowboy 09/20/14 10:01:26 PM
#6557   tom..thanks for your detailed TA,always very much appreciated.I novicetrader 09/20/14 08:57:14 PM
#6556   So this will be a change to the tim779 09/20/14 05:35:31 PM
#6555   LOL....the PR is not out yet. Dominic must vorlon1966 09/20/14 03:25:57 PM
#6554   So why does the agenda for SITC not tim779 09/20/14 02:44:10 PM
#6553   WHY PV-10 IS A BLOCKBUSTER FOR MELANOMA ALONE robofat 09/20/14 02:40:22 PM
#6552   New Moffitt Study vorlon1966 09/20/14 11:07:29 AM
#6551   Maybe they just got a tip regarding the one_would_believe 09/20/14 04:30:31 AM
#6550   If someone wanted to buy 2 million shares tim779 09/19/14 10:48:55 PM
#6549   That may make sense given the rumours I've FortStCowboy 09/19/14 05:28:00 PM
#6548   Anyone else notice the last trade of the AlwaysFriday 09/19/14 04:55:30 PM
#6547   The market could be going up, down, or big orange 09/19/14 04:06:49 PM
#6546   lol okay you can have the most stale WealthyKing 09/19/14 02:40:41 PM
#6545   @ w king....we might need to share the 123tom 09/19/14 02:32:59 PM
#6544   While on the NYSE the specialists are keeping vorlon1966 09/19/14 12:54:50 PM
#6543   well, it hit 1.12 like I said it WealthyKing 09/19/14 10:25:51 AM
#6542   @ novicetrader,,,,hard to say for sure.... 123tom 09/19/14 12:38:53 AM
#6541   123tom - I totally identify with your post! pacificnorthwest1 09/18/14 09:58:04 PM
#6540   the good thing is that this has held novicetrader 09/18/14 09:50:43 PM
#6539   ....Alan Ross interview and commentary from a few 123tom 09/18/14 04:26:05 PM
#6538   @Wealthy(slightly less wealthy) King..... 123tom 09/18/14 03:18:56 PM
#6537   Thoughts from my esteemed colleagues on today's price FortStCowboy 09/18/14 01:58:59 PM
#6536   Time to load again.all MM siting here for cheaps Ice86 09/18/14 12:08:13 PM
#6535   I love voodoo donuts! kanox 09/18/14 02:51:42 AM
#6534   Is it donut time or not yet? pacificnorthwest1 09/17/14 08:21:44 PM
#6533   thanks E, for that little present...very 123tom 09/17/14 03:17:04 PM
#6532   Love it! You'll have no trouble getting funding FortStCowboy 09/17/14 03:11:25 PM
#6531   What year? pacificnorthwest1 09/17/14 02:51:44 PM
#6530   "Liver Blockbuster article" Itsallriggedanyways 09/17/14 02:45:57 PM
#6529   Don't know where it came from but thought FortStCowboy 09/17/14 02:12:36 PM
#6528   I'm looking at these basic support targets below.... 123tom 09/17/14 01:36:50 PM
#6527   90 days from the pr announcing it. vorlon1966 09/17/14 12:41:59 PM
#6526   When is MOU deadline? KPS88 09/17/14 12:32:46 PM
#6525   BTW....none of the events are FDA dependent. vorlon1966 09/17/14 12:06:07 PM
#6524   While anything is possible....I believe it is highly vorlon1966 09/17/14 11:44:47 AM
#6523   Will the .85 and .86 cent gap become possible?????? pacificnorthwest1 09/17/14 11:20:07 AM
#6522   CTD news:September 16-How much is enough, and when? pacificnorthwest1 09/16/14 09:52:55 PM
#6521   a song for tom123 pacificnorthwest1 09/16/14 06:53:32 PM
#6520   haha WealthyKing 09/16/14 05:05:25 PM
#6519   ok....we're betting a bag of stale donuts here. 123tom 09/16/14 04:13:19 PM
#6518   that unfortunately is wishful thinking and doubtful to occur. WealthyKing 09/16/14 04:10:31 PM
#6517   On the short term intraday chart, today looks 123tom 09/16/14 03:36:49 PM
#6516   PVCT should be in the 1.20-30's today based WealthyKing 09/16/14 02:22:36 PM
PostSubject